Freeline Therapeutics is a clinical stage company focused on treatment of chronic systemic diseases with liver targeted adeno-associated virus (AAV) gene therapy, announces today that it has raised over £88 million of new capital in a Series B financing round. Syncona Ltd (“Syncona”) led the new investment committing £85 million, with The UCL Technology Fund, committing £3.4 million to the series B funding. This augments the previous £33.5 million Series A investment from founding investor Syncona.
The funds will enable Freeline to drive its leading programs in Haemophilia B and Fabry Disease through clinical development and support the progress of the pipeline. In addition, it enables Freeline to further enhance its already substantial manufacturing and analytics capabilities with the aim of delivering high quality novel products to patients.
Freeline was set up in 2015 through a partnership between UCLB and Syncona, to further develop and commercialise the work of Professor Armit Nathwani emanating from his work at the UCL Cancer Institute. Professor Nathwani’s work has been generously supported by the MRC and the National Institute for Health Research University College London Hospitals Biomedical Research Centre (UCLH NIHR BRC)
Anne Prener, Chief Executive Officer of Freeline, said
“We are delighted to have secured Series B financing with Syncona and UCLTF today which will enable us to continue to expand the portfolio of clinical stage programmes and our proprietary manufacturing platform. Freeline has made significant progress and is now a clinical stage company with an exciting pipeline of innovative products for diseases with significant unmet needs and extensive manufacturing capabilities. Establishing our fully integrated AAV gene therapy platform has been a key focus since the Company’s inception, allowing secure and timely manufacture of products using our cutting-edge manufacturing technologies. The additional funding will enable us to continue this important work.”